Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon Lifts Q2 Earnings Guidance on Solid Sales in Japan, US, China
October 23, 2019
- European Panel Snubs Daiichi Sankyo’s Quizartinib
October 21, 2019
- JAK Debuts Draw Near in Japan Atopic Dermatitis Market, 1st Likely to Get Listing Next Spring
October 21, 2019
- FDA OKs Xofluza for Flu Patients Carrying High Complication Risks
October 21, 2019
- Shionogi, Janssen, Alzheimer’s Drug Discovery Foundation Join Forces to Develop AD Biomarkers
October 21, 2019
- Kyowa Kirin Recalling Mitomycin over Unauthorized Manufacturing Method, Supply Won’t Resume until 2021
October 18, 2019
- US FDA Panel Backs Shionogi’s Novel Antibiotic
October 18, 2019
- Sumitomo Dainippon Drops Bid to Buy Cynata
October 18, 2019
- FDA Gives Priority Status to Daiichi Sankyo/AZ’s HER2-Tageting ADC
October 18, 2019
- Ranitidine Compensation Programs Draw Complaints from Pharmacists, Separate Billing Seen “Unrealistic”
October 17, 2019
- Xofluza Filed in Japan for Post-Exposure Prophylaxis
October 17, 2019
- Asahi Kasei Initiates Voluntary Recall of Nafamostat after Glass Fragment Found in Vial
October 17, 2019
- Takeda to Divest 30 OTC, Non-Core Assets to Swiss Firm
October 16, 2019
- Astellas to Sell 3 Asian Products to Daiichi Sankyo for 9.6 Billion Yen
October 16, 2019
- FDA OKs 1st Schizophrenia Patch Drug: Hisamitsu
October 16, 2019
- Eisai’s Fycompa Gets China Thumbs-Up
October 16, 2019
- No Major Drug Supply Disruption after Typhoon Hagibis
October 16, 2019
- Sakigake-Designated Radiation Therapy Agent Filed in Japan
October 16, 2019
- OrphanPacific to Take Over Marketing Authorization for MSD’s Diazoxide
October 16, 2019
- Sanofi, Kaken to Wind Up Clexane Partnership
October 16, 2019
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…